Quantitative Biology > Tissues and Organs
[Submitted on 30 Mar 2020 (this version), latest version 3 May 2020 (v2)]
Title:Repurposed drugs for treating lung injury in COVID-19
View PDFAbstract:Lung injury with severe respiratory failure is the leading cause of death in COVID-19. Inhibition of ACE2 caused by spike protein of (SARS)-CoV-2 is the most plausible mechanism of lung injury in COVID-19. We proposed six candidate drugs, including geldanamycin, panobinostat, trichostatin A, narciclasine, COL-3 and CGP-60474, that could best reverse abnormal gene expression caused by (SARS)-CoV-2-induced inhibition of ACE2 in lung cells, for the promise of treating lung injuries in COVID-19.
Submission history
From: Bing He [view email][v1] Mon, 30 Mar 2020 03:36:44 UTC (284 KB)
[v2] Sun, 3 May 2020 05:34:24 UTC (1,255 KB)
References & Citations
Bibliographic and Citation Tools
Bibliographic Explorer (What is the Explorer?)
Litmaps (What is Litmaps?)
scite Smart Citations (What are Smart Citations?)
Code, Data and Media Associated with this Article
CatalyzeX Code Finder for Papers (What is CatalyzeX?)
DagsHub (What is DagsHub?)
Gotit.pub (What is GotitPub?)
Papers with Code (What is Papers with Code?)
ScienceCast (What is ScienceCast?)
Demos
Recommenders and Search Tools
Influence Flower (What are Influence Flowers?)
Connected Papers (What is Connected Papers?)
CORE Recommender (What is CORE?)
arXivLabs: experimental projects with community collaborators
arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website.
Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them.
Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.